BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28083020)

  • 1. Analysis of liver function test abnormalities in kidney transplant recipients: 7 year experience.
    Dizdar OS; Ersoy A; Aksoy S; Ozel Coskun BD; Yildiz A
    Pak J Med Sci; 2016; 32(6):1330-1335. PubMed ID: 28083020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncommon side effect of MMF in renal transplant recipients.
    Balal M; Demir E; Paydas S; Sertdemir Y; Erken U
    Ren Fail; 2005; 27(5):591-4. PubMed ID: 16152998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis.
    Shendi AM; Hung RKY; Caplin B; Griffiths P; Harber M
    Saudi J Kidney Dis Transpl; 2019; 30(3):606-614. PubMed ID: 31249224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: A single center experience.
    Yadav SK; Saigal S; Choudhary NS; Saha S; Sah JK; Saraf N; Kumar N; Goja S; Rastogi A; Bhangui P; Soin AS
    Transpl Infect Dis; 2018 Aug; 20(4):e12905. PubMed ID: 29668120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
    Couzi L; Helou S; Bachelet T; Martin S; Moreau K; Morel D; Lafon ME; Garrigue I; Merville P
    Transplant Proc; 2012 Nov; 44(9):2809-13. PubMed ID: 23146529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
    Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
    Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infectious complications in kidney transplant recipients: a single-center experience.
    Charfeddine K; Zaghden S; Kharrat M; Kamoun K; Jarraya F; Hachicha J
    Transplant Proc; 2005; 37(6):2823-5. PubMed ID: 16182820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?
    Basic-Jukic N; Kes P; Bubic-Filipi LJ; Puretic Z; Brunetta B; Pasini J
    Transplant Proc; 2005 Mar; 37(2):850-1. PubMed ID: 15848553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is antibody-mediated rejection in kidney transplant recipients a risk factor for developing cytomegalovirus or BK virus infection? Results from a case-control study.
    Los-Arcos I; Len O; Perello M; Torres IB; Codina G; Esperalba J; Sellarés J; Moreso F; Seron D; Gavaldà J
    J Clin Virol; 2019 Jan; 110():45-50. PubMed ID: 30537648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients.
    Sullivan T; Brodginski A; Patel G; Huprikar S
    Transplantation; 2015 Apr; 99(4):855-9. PubMed ID: 25208322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is cytomegalovirus infection related to mycophenolate mofetil after kidney transplantation? A case-control study.
    Sarmiento JM; Munn SR; Paya CV; Velosa JA; Nguyen JH
    Clin Transplant; 1998 Oct; 12(5):371-4. PubMed ID: 9787943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past.
    Wang EH; Partovi N; Levy RD; Shapiro RJ; Yoshida EM; Greanya ED
    Transpl Infect Dis; 2012 Oct; 14(5):519-25. PubMed ID: 22571389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.
    Tarasewicz A; Dębska-Ślizień A; Rutkowski B
    Transplant Proc; 2016 Jun; 48(5):1650-3. PubMed ID: 27496465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-transplant cytomegalovirus immunoglobulin G antibody levels could prevent severe cytomegalovirus infections post-transplant in liver transplant recipients: Experience from a tertiary care liver centre.
    Gupta E; Pamecha V; Verma Y; Kumar N; Rastogi A; Hasnian N; Bhadoria AS
    Indian J Med Microbiol; 2017; 35(4):499-503. PubMed ID: 29405140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M; Dengler T; Mattei MF; Poncelet A; Vanhaecke J; Vermes E; Kleinloog R; Li Y; Gezahegen Y; Delgado JF;
    Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-center experience with mycophenolate mofetil in pediatric renal transplant recipients.
    Virji M; Carter JE; Lirenman DS
    Pediatr Transplant; 2001 Aug; 5(4):293-6. PubMed ID: 11472609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.